199 related articles for article (PubMed ID: 23909154)
1. Presentation and management of gastrointestinal stromal tumours.
Mongan AM; Malik V; Rowley S; Claxton Z; Muldoon C; O'Toole D; Ravi N; Reynolds JV
Ir Med J; 2013 Jun; 106(6):176-9. PubMed ID: 23909154
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
4. [New prospective on adjuvant treatment for gastrointestinal stromal tumors].
Pan ZZ; Wu XJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):212-5. PubMed ID: 23536337
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
Li J; Dang YZ; Gao J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):216-20. PubMed ID: 23536338
[TBL] [Abstract][Full Text] [Related]
6. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.
Jakob J; Mussi C; Ronellenfitsch U; Wardelmann E; Negri T; Gronchi A; Hohenberger P
Ann Surg Oncol; 2013 Feb; 20(2):586-92. PubMed ID: 22965573
[TBL] [Abstract][Full Text] [Related]
8. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
Kang YK; Kang BW; Im SA; Lee JL; Park SR; Kang WK; Chang HM; Kim TW; Oh DY; Jung KH; Ryu MH
Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
[TBL] [Abstract][Full Text] [Related]
9. NCCN Task Force report: gastrointestinal stromal tumor (GIST).
Demetri G; DeMatteo RP
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-25-8. PubMed ID: 23570095
[No Abstract] [Full Text] [Related]
10. A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors.
Ogata K; Mochiki E; Ojima H; Haga N; Fukuchi M; Aihara R; Ando H; Uchida N; Toyomasu Y; Suzuki M; Kimura A; Kogure N; Yokobori T; Ohno T; Kuwano H
J Surg Oncol; 2014 Dec; 110(8):942-6. PubMed ID: 25164620
[TBL] [Abstract][Full Text] [Related]
11. Successful resection of a giant recurrent gastrointestinal stromal tumour with imatinib mesylate as neoadjuvant therapy.
Yu JR; Yang XJ; Yang WL; Gao Y; Zhang Q
Scand J Gastroenterol; 2007 Sep; 42(9):1138-40. PubMed ID: 17710683
[TBL] [Abstract][Full Text] [Related]
12. [GIST: our experience].
Rossi MT; Fasano G; Morlino A; Scutari F
G Chir; 2009; 30(1-2):41-5. PubMed ID: 19272232
[TBL] [Abstract][Full Text] [Related]
13. [Clinical analysis of 79 gastrointestinal tract stromal tumor cases].
Liu ZM; Liang J; Yu Z
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):552-3. PubMed ID: 22093639
[No Abstract] [Full Text] [Related]
14. Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST.
Gasparotto D; Miolo G; Torrisi E; Canzonieri V; Bertola G; Libra M; Marzotto A; Maestro R; Buonadonna A
Int J Colorectal Dis; 2014 May; 29(5):639-40. PubMed ID: 24525699
[No Abstract] [Full Text] [Related]
15. Gastrointestinal stromal tumors: diagnosis and treatment.
Acín-Gándara D; Pereira-Pérez F; Castaño-Pascual A; Durán-Poveda M; Antequera-Pérez A; Miliani-Molina C
Cir Cir; 2012; 80(1):44-51. PubMed ID: 22472152
[TBL] [Abstract][Full Text] [Related]
16. [How should patients with completely resected gastrointestinal stromal tumours (GIST) be followed up?].
Stelzner S; Antoni C; Haroske G; Jacobasch L; Erk JU; Ludwig K
Zentralbl Chir; 2005 Dec; 130(6):554-61. PubMed ID: 16382404
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
Jiang WZ; Guan GX; Lu HS; Yang YH; Kang DY; Huang HG
J Surg Oncol; 2011 Dec; 104(7):760-4. PubMed ID: 21713778
[TBL] [Abstract][Full Text] [Related]
18. [Prognosis analysis of 216 cases of gastrointestinal stromal tumor].
Liu LC; Xu WT
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Mar; 15(3):255-8. PubMed ID: 22454172
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
DeMatteo RP; Ballman KV; Antonescu CR; Corless C; Kolesnikova V; von Mehren M; McCarter MD; Norton J; Maki RG; Pisters PW; Demetri GD; Brennan MF; Owzar K;
Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
[TBL] [Abstract][Full Text] [Related]
20. Resection of focally progressive gastrointestinal stromal tumours resistant to imatinib therapy.
Tse GH; Wong EH; O'Dwyer PJ
Surgeon; 2012 Dec; 10(6):309-13. PubMed ID: 22123434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
